Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Invested Capital (2019 - 2026)

ADC Therapeutics has reported Invested Capital over the past 8 years, most recently at -$91.6 million for Q1 2026.

  • Quarterly results put Invested Capital at -$91.6 million for Q1 2026, up 19.25% from a year ago — trailing twelve months through Mar 2026 was -$91.6 million (up 19.25% YoY), and the annual figure for FY2025 was -$61.1 million, up 21.58%.
  • Invested Capital reached -$91.6 million in Q1 2026 per ADCT's latest filing, down from -$61.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $434.5 million in Q4 2022 and bottomed at -$113.5 million in Q1 2025.
  • Median Invested Capital over the past 5 years was -$62.7 million (2023), compared with a mean of -$21.5 million.
  • The largest annual shift saw Invested Capital surged 64.82% in 2024 before it tumbled 974.23% in 2025.
  • Over 5 years, Invested Capital stood at $434.5 million in 2022, then tumbled by 105.41% to -$23.5 million in 2023, then crashed by 231.37% to -$77.9 million in 2024, then rose by 21.58% to -$61.1 million in 2025, then tumbled by 49.99% to -$91.6 million in 2026.
  • Business Quant data shows Invested Capital for ADCT at -$91.6 million in Q1 2026, -$61.1 million in Q4 2025, and -$113.4 million in Q3 2025.